TNSN04035A1 - Azithromycine en dose unique - Google Patents

Azithromycine en dose unique

Info

Publication number
TNSN04035A1
TNSN04035A1 TNP2004000035A TNSN04035A TNSN04035A1 TN SN04035 A1 TNSN04035 A1 TN SN04035A1 TN P2004000035 A TNP2004000035 A TN P2004000035A TN SN04035 A TNSN04035 A TN SN04035A TN SN04035 A1 TNSN04035 A1 TN SN04035A1
Authority
TN
Tunisia
Prior art keywords
azithromycin
single dose
humans
administering
relates
Prior art date
Application number
TNP2004000035A
Other languages
English (en)
Inventor
Michael William Dunne
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN04035A1 publication Critical patent/TNSN04035A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE UNE METHODE DE TRAITEMENT D'INFECTIONS RESPIRATOIRES CHEZ L'HOMME EN ADMINISTRANT UNE DOSE UNIQUE D'AZITHROMYCINE.
TNP2004000035A 2001-08-21 2004-02-20 Azithromycine en dose unique TNSN04035A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31386701P 2001-08-21 2001-08-21
PCT/IB2002/003076 WO2003018031A2 (fr) 2001-08-21 2002-07-31 Azithromycine unidose

Publications (1)

Publication Number Publication Date
TNSN04035A1 true TNSN04035A1 (fr) 2006-06-01

Family

ID=23217490

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000035A TNSN04035A1 (fr) 2001-08-21 2004-02-20 Azithromycine en dose unique

Country Status (25)

Country Link
US (3) US20030148964A1 (fr)
EP (1) EP1418924A2 (fr)
JP (1) JP2005501862A (fr)
KR (1) KR20040032942A (fr)
AP (1) AP1729A (fr)
BG (1) BG108537A (fr)
BR (1) BR0211830A (fr)
CA (1) CA2458135A1 (fr)
CZ (1) CZ2004232A3 (fr)
EA (1) EA200400214A1 (fr)
EC (1) ECSP044985A (fr)
GE (1) GEP20063812B (fr)
HR (1) HRP20040163A2 (fr)
HU (1) HUP0401332A2 (fr)
IL (1) IL159585A0 (fr)
IS (1) IS7092A (fr)
MA (1) MA27059A1 (fr)
MX (1) MXPA04001605A (fr)
OA (1) OA12845A (fr)
PL (1) PL367888A1 (fr)
SK (1) SK1012004A3 (fr)
TN (1) TNSN04035A1 (fr)
WO (1) WO2003018031A2 (fr)
YU (1) YU8804A (fr)
ZA (1) ZA200400804B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004019288D1 (de) * 2003-07-24 2009-03-19 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
CA2547597A1 (fr) 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions multiparticulaires a stabilite amelioree
ES2308274T3 (es) 2003-12-04 2008-12-01 Pfizer Products Inc. Procedimiento para fabricar multiparticulados farmaceuticos.
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CA2838111C (fr) 2005-12-08 2016-01-19 Insmed Incorporated Compositions a base de lipide d'anti-infectieux pour traiter des infections pulmonaires et procedes d'utilisation de celles-ci
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US20090005326A1 (en) * 2007-06-26 2009-01-01 Idexx Laboratories, Inc. Single dose roxithromycin
US20090197956A1 (en) * 2008-02-04 2009-08-06 Arbor Pharmaceuticals, Inc. Treatment of acute otitis media with xylitol and n-acetylcysteine
US20110105421A1 (en) * 2008-03-14 2011-05-05 The Florida International University Board Of Trustees Ellagitannins as inhibitors of bacterial quorum sensing
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
EP3581186A1 (fr) 2012-11-29 2019-12-18 Insmed Incorporated Formulations de vancomycine stabilisées
PL3142643T3 (pl) * 2014-05-15 2019-12-31 Insmed Incorporated Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
EP3773505A4 (fr) 2018-03-30 2021-12-22 Insmed Incorporated Procédés pour la fabrication continue de produits médicamenteux liposomaux
WO2021163451A1 (fr) * 2020-02-14 2021-08-19 Asklepios Biopharmaceutical, Inc. Procédé de traitement d'une toxicité associée à une thérapie génique avec des antibiotiques

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US53264A (en) * 1866-03-20 Improved ditching-machine
YU43116B (en) * 1979-04-02 1989-04-30 Pliva Pharm & Chem Works Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RU2066324C1 (ru) * 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (fr) * 1987-09-10 1989-03-23 Pfizer Azithromycine et derives utilises comme agents anti-protozoaires
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
TW271400B (fr) * 1992-07-30 1996-03-01 Pfizer
DE69403963T2 (de) * 1993-05-19 1997-11-20 Pfizer Zwischenprodukt für azithromycin
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CZ292360B6 (cs) * 1994-05-06 2003-09-17 Pfizer Inc. Dávkovací forma s řízeným uvolňováním obsahující azithromycin a způsob její výroby
HRP980189B1 (en) * 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US20040053264A1 (en) * 2002-02-01 2004-03-18 Park Sung Sup Clinical panel assay using DNA chips

Also Published As

Publication number Publication date
PL367888A1 (en) 2005-03-07
CA2458135A1 (fr) 2003-03-06
WO2003018031A2 (fr) 2003-03-06
US6987093B2 (en) 2006-01-17
EP1418924A2 (fr) 2004-05-19
ECSP044985A (es) 2004-04-28
AP2004002968A0 (en) 2004-03-31
AP1729A (en) 2007-03-26
IL159585A0 (en) 2004-06-01
YU8804A (sh) 2006-08-17
CZ2004232A3 (cs) 2005-10-12
HRP20040163A2 (en) 2005-02-28
GEP20063812B (en) 2006-05-10
BR0211830A (pt) 2004-09-08
EA200400214A1 (ru) 2004-06-24
US7067493B2 (en) 2006-06-27
WO2003018031A3 (fr) 2003-10-02
MA27059A1 (fr) 2004-12-20
BG108537A (bg) 2005-02-28
OA12845A (en) 2006-09-15
US20050250712A1 (en) 2005-11-10
US20030148964A1 (en) 2003-08-07
IS7092A (is) 2003-12-23
SK1012004A3 (sk) 2005-04-01
KR20040032942A (ko) 2004-04-17
MXPA04001605A (es) 2004-07-08
US20040023898A1 (en) 2004-02-05
ZA200400804B (en) 2005-05-03
JP2005501862A (ja) 2005-01-20
HUP0401332A2 (hu) 2004-11-29

Similar Documents

Publication Publication Date Title
TNSN04035A1 (fr) Azithromycine en dose unique
BR0109165A (pt) Método de tratamento de pólipos colÈnicos
CY1108578T1 (el) Φαρμακευτικες συνθεσεις (κιτ) περιλαμβανοντας ενωσεις διϋδροπυριδινονης και εναν ανοσορυθμιστικο (ή εναν αντιφλεγμονωδη) παραγοντα και οι χρησεις αυτων
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
BG101118A (en) Therapeutical compounds
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
ATE343388T1 (de) Pde-v hemmer zur behandlung von morbus parkinson
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
EA200401114A2 (ru) Замещённые гидроксиэтиламины
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
HUP0500039A2 (hu) Vakcina és eljárás mozgatóneuron-betegségek kezelésére
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0211635A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um indivìduo sofrendo de ou propenso à doença de alzheimer
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
SE0004101D0 (sv) New use
TR200101841T2 (tr) Enfeksiyonlardan korunmak ve enfeksiyon tedavisi için bifosfonatların kullanılmaları
ATE290384T1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes